VGXI has reopened and we are getting back to normal operations. Our thoughts are with all those who have been affected by Hurricane Harvey, including our employees, their families, and all our neighbors in the area. For any who would like to contribute to the recovery effort, please consider a donation to one of the… Read More »
Update: VGXI will open for business on Thursday, August 31, 2017. To ensure the safety of our employees and their families, VGXI closed from Monday through Wednesday, August 28th – 30th, 2017. Please stay safe and check back on our website or facebook page for updates.
Heading to Paris in October? Meet with representatives from VGXI and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. 2017 International Society of Vaccines Annual Congress October 5 – 7, 2017 Institute Pasteur Paris, France
VGXI announced that on April 10th, 2017 the corporation won the award for Best Production / Process Development at the 10th Annual ViE Awards Ceremony held at the 2017 World Vaccine Congress in Washington, D.C.
IVI and GeneOne Life Science to collaborate in clinical development of GeneOne’s DNA-based MERS-CoV vaccine. The collaboration will accelerate vaccine development and ensure access for public health readiness in case of future outbreaks in Korea and worldwide. Signing ceremony for MERs-CoV vaccine development collaboration. The International Vaccine Institute (IVI) and GeneOne Life Science Inc. have… Read More »
On November 18, 2016 VGXI hosted a roundtable discussion with US Congressman Pete Olson and key biotech industry leaders. From left: U.S. Congressman Pete Olson; Ann Tanabe, CEO of BioHouston; Young Park, CEO of GeneOne Life Science; Jim Greenwood, President of BIO; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO… Read More »
SEOUL, KOREA (PRWEB) JULY 26, 2016 GeneOne Life Science, Inc. (“GeneOne” KOSPI: 011000) today announced the dosing of the first subjects in its multi-center Phase I trial to evaluate the Zika DNA vaccine (GLS-5700). Refer to ClinicalTrials.Gov, study number NCT02809443. GeneOne has received approval from both the US FDA and Health Canada’s Health Products and… Read More »
On July 13th, 2016 VGXI was featured on KPRC Channel 2 News for their role in manufacturing the first Zika DNA Vaccine approved by the FDA for testing in human clinical trials. Follow this this link or click below to read the full story and watch the video: For more information, contact: Christy Franco, PhD… Read More »
U.S. Congressman Kevin Brady visits VGXI to celebrate the grand opening for their new small scale cGMP manufacturing facility, located in The Woodlands, TX. VGXI Ribbon Cutting, from left: J.J. Hollie, President and CEO of The Woodlands Chamber of Commerce; U.S. Congressman Kevin Brady; Young Park, CEO of GeneOne Life Science; Dorothy Peterson, VP of… Read More »
On June 18th, 2015 VGXI celebrated the opening of the Advanced Biopharmaceuticals International Center of Support (ABICS) at their facility in The Woodlands, TX. View the video below. In response to the recent MERS outbreak, the Texas-based clinical manufacturing organization, VGXI has rapidly mobilized in collaboration with the Korean company GeneOne Life sciences to expedite… Read More »
VGXI supports expedited development and scale-up of multiple vaccine candidates to treat Ebola through a DARPA funded collaboration. Click below to view the video. US Congressman Kevin Brady visited the VGXI manufacturing facility in The Woodlands, TX on May 4th, 2015 to tour the production plant and provide a statement on the impact of this… Read More »
Positive clinical data has been published for a cystic fibrosis gene therapy clinical trial supported by the cGMP plasmid DNA manufacturing services of the Texas-based CMO, VGXI. Recently, the United Kingdom Cystic Fibrosis Gene Therapy Consortium (UKCFGTC) published the first clinical data from a Phase IIb, multi-dose clinical trial for cystic fibrosis. In this trial,… Read More »